Abstract
In the light of the recent randomized controlled trials in chronic heart failure, it is now commonly assumed that treatment with an angiotensin-receptor blocker (ARB) is equivalent to treatment with an angiotensin-converting enzyme (ACE) inhibitor. We performed an imputed placebo analysis using previous placebo-ACE inhibitor trials and the current ACE inhibitor-ARB comparison studies, which shows that ARBs may not even be superior to placebos, let alone an ACE inhibitor.
Publication types
-
Comparative Study
-
Editorial
MeSH terms
-
Aged
-
Angiotensin Receptor Antagonists*
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Captopril / adverse effects
-
Captopril / therapeutic use*
-
Cause of Death
-
Chronic Disease
-
Heart Failure / drug therapy*
-
Heart Failure / mortality
-
Heart Failure / physiopathology
-
Humans
-
Losartan / adverse effects
-
Losartan / therapeutic use*
-
Prospective Studies
-
Randomized Controlled Trials as Topic
-
Receptors, Angiotensin / physiology
-
Survival Rate
-
Treatment Outcome
Substances
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Receptors, Angiotensin
-
Captopril
-
Losartan